FDA approves brain stimulation device for Parkinson's disease

June 14, 2015
FDA approves brain stimulation device for parkinson's disease
Brio Neurostimulation System is second such device approved for tremor disorders.

(HealthDay)—The U.S. Food and Drug Administration on Friday approved a device that can be implanted into the brain to help people battling Parkinson's disease.

The Brio Neurostimulation System is "an implantable to help reduce the symptoms of Parkinson's disease and essential tremor, a movement disorder that is one of the most common causes of tremors," the FDA said in a news release.

The agency estimates that about 50,000 Americans are diagnosed with Parkinson's annually, while essential tremor affects "several million" people, most over the age of 40.

"There are no cures for Parkinson's disease or essential tremor, but finding better ways to manage symptoms is essential for patients," Dr. William Maisel, acting director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, said in the news release.

"This new device adds to the array of treatment options to help people living with Parkinson's and essential tremor enjoy better, more productive lives," he said.

The device is consists of a small, rechargeable battery-powered "pulse generator" implanted under the skin. Wire leads from the generator lead to specific brain locations, depending on the illness under treatment. People trained in using the devices can adjust the pulse generator's effects as needed, the FDA said.

The Brio Neurostimulation System was approved based on the results of two clinical trials, one involving 136 patients with Parkinson's disease who used the device for three months, and another involving 127 patients with essential tremor who used it for six months. In both studies, medications had already failed to control patients' symptoms, the FDA said.

"Both groups showed statistically significant improvement on their primary effectiveness endpoint when the device was turned on, compared to when it was turned off," the agency said.

The device does not come without risk, including intracranial bleeding which can lead to stroke, paralysis or death, the FDA said. Infection and device dislocation are also potential risks.

"Brio Neurostimulation System is the second device approved by the FDA for Parkinson's and essential tremor," the agency said. "The first device, Medtronic's Activa Deep Brain Stimulation Therapy System, was approved in 1997 for tremor associated with and Parkinson's disease. In 2002, the indications were expanded to include the symptoms of Parkinson's disease."

Explore further: Focused ultrasound for treating Parkinson's disease to be tested

More information: There's more on Parkinson's disease at the National Parkinson's Foundation.

Related Stories

Focused ultrasound for treating Parkinson's disease to be tested

October 12, 2012
(Medical Xpress)—After a promising clinical trial of focused ultrasound as a potential treatment for essential tremor, the University of Virginia Health System is launching a new study to investigate the scalpel-free technology's ...

Demand-driven deep brain stimulation to treat Parkinson's disease

April 15, 2015
Researchers from the Centre for Biomedical Technology (CTB) at Universidad Politécnica de Madrid (UPM) have participated in a joint research project with Universidad Carlos III de Madrid and University of Reading (United ...

Medtronic device will collect data as it treats brain disorders

August 13, 2013
A new deep brain stimulation system by Medtronic can sense and record brain activity at the same time it delivers therapy to treat Parkinson's symptoms, essential tremors and epilepsy. The data collected by the Activa PC+S ...

DBS operation for Parkinson's disease performed inside iMRI

September 19, 2011
Henry Ford Hospital became the third hospital in the United States to perform a Deep Brain Stimulation (DBS) procedure inside an Intraoperative Magnetic Resonance Imaging scanner, or iMRI.

Spinal stimulation system relieves pain without tingling

May 11, 2015
(HealthDay)—The Senza spinal cord stimulation system has been approved by the U.S. Food and Drug Administration to treat chronic back pain without the tingling sensation that characterizes more traditional pain-relieving ...

Recommended for you

Link between tuberculosis and Parkinson's disease discovered

May 22, 2018
The mechanism our immune cells use to clear bacterial infections like tuberculosis (TB) might also be implicated in Parkinson's disease, according to a new collaborative study led by scientists from the Francis Crick Institute ...

Link between IBD and Parkinson's might allow doctors to slow down condition

May 21, 2018
Doctors may be able to modify or slow down the progress of the neurological condition Parkinson's disease in the future by spotting signs of it in patients with inflammatory bowel disease (IBD), suggest a study published ...

Untangling brain neuron dysfunction in Parkinson's disease and dementia with Lewy bodies

May 10, 2018
A decay of brain function is a hallmark of Parkinson's disease and dementia with Lewy bodies, or DLB. Specifically, cognitive dysfunction defines DLB, and nearly eight of every 10 Parkinson's patients develop dementia.

Diverse Parkinson's-related disorders may stem from different strains of same protein

May 9, 2018
Different Parkinson's-related brain disorders, called synucleionpathies, are characterized by misfolded proteins embedded in cells. Researchers in the Perelman School of Medicine at the University of Pennsylvania found that ...

New study sheds light on the complex dynamics of Parkinson's disease

May 3, 2018
Parkinson's disease affects around 10 million people worldwide, yet exactly how the disease and treatments for its symptoms work remains a bit mysterious. Now, Stanford researchers have tested a seminal theory of Parkinson's ...

Researchers find that lipid accumulation in the brain may be an early sign of Parkinson's disease

April 29, 2018
A collaborative team of researchers at McLean Hospital, a Harvard Medical School affiliate, and Oxford University has found that elevated levels of certain types of lipids (fat molecules) in the brain may be an early sign ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.